Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Oct '13
|
Lord Glendonbrook
|
|
Stryker / NYQ:SYK |
£69.42
|
£357.14
|
414.46%
|
£360,123.91
|
May '11
|
Lord Glendonbrook
|
|
Abbott Laboratories / NYQ:ABT |
£25.27
|
£112.42
|
344.94%
|
£311,458.74
|
Jan '13
|
Lord Sassoon
|
|
Abbott Laboratories / NYQ:ABT |
£32.90
|
£112.42
|
241.70%
|
£239,191.47
|
Apr '21
|
Lord Grabiner
|
|
Boston Scientific / NYQ:BSX |
£39.32
|
£88.66
|
125.48%
|
£157,838.26
|
Nov '23
|
Lord Mance
|
|
Stryker / NYQ:SYK |
£275.00
|
£357.14
|
29.87%
|
£90,908.37
|
Apr '10
|
Baroness Noakes
|
|
Smith & Nephew / NYQ:SNN |
£20.98
|
£24.79
|
18.16%
|
£82,710.56
|
May '15
|
Lord Glendonbrook
|
|
Medtronic / NYQ:MDT |
£78.41
|
£86.77
|
10.66%
|
£77,463.33**
|
May '11
|
Lord Glendonbrook
|
|
Smith & Nephew / NYQ:SNN |
£22.61
|
£24.79
|
9.67%
|
£76,766.06
|
May '23
|
Lord Londesborough
|
|
Abbott Laboratories / NYQ:ABT |
£108.82
|
£112.42
|
3.31%
|
£72,315.75
|
Nov '17
|
Lord Howard of Rising
|
|
Ekf Diagnostics / LSE:EKF.L |
£25.01
|
£24.00
|
-4.04%
|
£67,172.59
|
Dec '19
|
Lord Glendonbrook
|
|
Align Technology / NMS:ALGN |
£273.75
|
£213.58
|
-21.98%
|
£54,614.06
|
Jan '24
|
Lord Kakkar
|
|
Cyte / NMS:CTKB |
£8.31
|
£6.19
|
-25.51%
|
£52,142.00
|
Dec '23
|
Lord Browne of Madingley
|
|
Allurion / NYQ:ALUR |
£3.31
|
£0.28
|
-91.54%
|
£5,921.45
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.